Edition:
India

People: Catalyst Biosciences Inc (CBIO.OQ)

CBIO.OQ on NASDAQ Stock Exchange Capital Market

5.24USD
21 Nov 2019
Change (% chg)

-- (--)
Prev Close
$5.24
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
31,210
52-wk High
$11.27
52-wk Low
$4.52

Levy, Howard 

Dr. Howard Levy M.B.B.Ch., Ph.D., M.M.M. is the Chief Medical Officer of the Company. Prior to joining us, from 2010 through April 2016, Dr. Levy had served as either a Chief Medical Officer or a consultant with various public and private biotechnology companies on clinical and drug development strategy and execution. In addition, Dr. Levy was the Senior Global Medical Program Director at CSL Behring in 2013, and he was the Senior Vice President and Chief Medical Officer at Inspiration Biopharmaceuticals, a company solely focused on innovation in hemophilia, in 2012. From 2008 to 2011, he served as Chief Medical Officer at Sangart, Inc., which was developing pegylated hemoglobin as an oxygen therapeutic agent and a treatment for sickle cell crisis. Prior to Sangart, from 2006 to 2008, Dr. Levy was Associate Vice President, Clinical Research, Medical and Regulatory Affairs, at Novo Nordisk and was responsible for a number of clinical research programs, including recombinant Factor VIIa. Earlier in his career, Dr. Levy was Clinical Research Physician and Medical Director, Acute Care in the U.S. Medical Division of Eli Lilly and Company supporting post-marketing clinical trials and medical affairs for recombinant Activated Protein C (Xigris) in severe sepsis and antiplatelet agents ReoPro and prasugrel. He was also Chief of Critical Care Medicine at the University of New Mexico in Albuquerque for 11 years. Dr. Levy holds M.B. B.Ch and Ph.D. degrees from University of the Witwatersrand in Johannesburg, South Africa and an M.M.M. from Carnegie Mellon University’s H. John Heinz III College..

Basic Compensation

Total Annual Compensation, USD 537,068
Restricted Stock Award, USD --
Long-Term Incentive Plans, USD --
All Other, USD 661,779
Fiscal Year Total, USD 1,198,850

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --